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The incidence of invasive fungal infections (IFIs) is significantly high in patients 
following lung transplantation. There have been no investigations on the pharmacokinetics of 
posaconazole in patients with CF. In this study, 7 patients with CF and 13 patients without CF 
were enrolled in a pharmacokinetic study upon initiation of posaconazole prophylaxis following 
lung transplantation. We established a sensitive HPLC-fluorescence assay method to measure 
plasma concentration of posaconazole. After a minimum five days of treatment, maximum 
plasma concentration Css, max (0.311 μg/mL) in CF patients was 56% lower compared to Css, max 
(0.699 μg/mL) in non-CF patients; the minimum plasma concentration Css, min (0.189·μg/mL) in 
CF patients was lower by 60% compared to Css, min (0.474 μg/mL) in non-CF patients; the 
average plasma concentration Css, av (0.233 μg/mL) in CF patients was lower by 61% compared 
to Css, av (0.594 μg/mL) in non-CF patients, the dose normalized plasma area under curve AUC0-
24 (0.007 h*μg/mL) in CF patients was 65% lower compared to dose normalized AUC0-24 (0.02 
h*μg/mL) in non-CF patients, and the apparent oral clearance of 2.51 L/h/kg in CF patients was 
3.4 times higher compared to 0.74 L/h/kg in non-CF patients. Moreover, a steady state average 
concentration of 0.7 μg/mL that is considered to be essentials for prophylaxis was only achieved 
in 4 out of 20 patients. A good correlation between Ctrough and AUC0-τ demonstrates Ctrough is a 
good surrogate marker to monitor systemic exposure of posaconazole in LTRs.  
 
POSACONAZOLE PHARMACOKINETICS IN LUNG TRANSPLANT RECEIPIENTS 
WITH AND WITHOUT CYSTIC FIBROSIS 
Hongfei Zhang, M.S., University of Pittsburgh, 2015 
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1.0  INTRODUCTION 
1.1 LUNG TRANSPLANTATION 
1.1.1 History of Lung Transplantation 
The foundation for clinical organ transplantation was laid by Alexis Carrel (1873-1944). In 1912, 
Dr. Carrel was awarded the first Nobel Prize in physiology and medicine in recognition of his 
groundbreaking contribution to vascular suture, and the transplantation of blood vessels and 
organs (1). In 1963, Dr. James Hardy conducted the first human lung transplantation, but the 
transplant recipient died after 18 days (2). Further, clinical lung transplantation was hampered by 
lack of effective immunosuppressive agents and suboptimal surgical techniques. Twenty years 
later, in 1982, the first successful human heart-lung transplantation was performed (3), and in the 
following year, Dr. Joel Cooper carried out the first successful human single lung transplantation 
with prolonged postoperative survival (4). 
Lung transplantation has become a treatment option for patients with end-stage lung 
disease over the past three decades. According to the 31st adult lung and heart-lung transplant 
report from the Registry of the International Society for Heart and Lung Transplantation, 47, 647 
adult lung transplants have been performed worldwide in 136 participating transplant centers 
from 1985 to 2013 (5). 
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1.1.2 Types of Lung Transplantation  
There are various types of lung transplantations including single lung transplantation, bilateral 
lung transplantation, heart-lung transplantation and lobar lung transplantation. Both single and 
bilateral lung transplantation are widely used in a variety of end-stage lung diseases. Single lung 
transplantation could be applied to all end-stage lung diseases except for patients with septic lung 
disease, which is an indication for bilateral lung transplantation. Although both single and 
bilateral lung transplantation have continued to increase since the 1980s, the growth of bilateral 
lung transplantation has exceeded single lung transplantation and has become the main form of 
lung transplantation performed currently. According to the 29th report of the Registry of the 
International Society for Heart and Lung Transplantation, conditional median survival 
(transplant half-life) of single lung transplantation is 6.5 years, while it is 9.4 years for bilateral 
lung transplantation (6). The more favorable median survival rate may be the reason that has led 
to the increased numbers of bilateral lungs transplanted. 
The indications for heart-lung transplantation are pulmonary vascular diseases, like 
congenital heart disease and primary pulmonary hypertension. After a decline in 2003, the 
number of heart-lung transplantation has stayed relatively stable. Around 100 cases are carried 
out worldwide every year (6). 
Living lobar lung transplantation is an alternative to cadaveric lung transplantation in 
which right and left lower lobes from two separate donors are removed and implanted in a 
recipient in place of the entire right and left lungs. Lobar lung transplantation remains a small 
part of the total number of lung transplantations performed currently (7). 
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1.1.3 Median Survival of Lung Transplantation 
In 2009, the conditional half-life of heart transplantation recipients was 14 years (8), while the 
conditional half-lives of liver and kidney transplantation were over 12 years (9) and over 10 
years (10) respectively. As of June 2010 overall median survival of single and bilateral lung 
transplantation was 5.5 years, and conditional median survival was 7.7 years (7). Currently, the 
median survival of lung transplantation is significantly lower compared with other solid organ 
transplantations. 
1.2 COMPLICATIONS AFTER LUNG TRANSPLANTATION 
1.2.1 Causes of Death in LTRs 
After lung transplantation, recipients may experience bronchiolitis, acute rejection, graft failure, 
malignancy, infections and cardiovascular diseases that can cause recipients’ death. 
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Figure 1. Allocation of causes of death in a time period following lung transplantation from 1992 to 
2011 
 
Figure 1 demonstrates that infections are one of the main reasons for the mortality of the 
LTRs and infections can result in death immediately after transplantation or over several years 
(6). Between 1992 and 2011, during the first year after lung transplantation, almost 40% of 
patients with infections died as a result of those infections (6). 
 
  5 
 
Figure 2. Risk factors for infections following lung transplantation 
 
As figure 2 shows, several reasons make infections more serious after lung 
transplantation than after other solid organ transplantations. For example, the body may be 
contaminated by the process of opening of the recipient’s airway during the lung transplant 
surgery. Also, lungs are the only organs that are under a constant exposure to environmental 
pathogens, which increases the chances of infections. Third, after lung transplantation, 
immunosuppression must be well maintained in the recipients. Infection is a direct result of the 
immunocompromised state of the LTRs. Moreover, lung infections can be caused by other 
concomitant infections in the recipients. 
Infections
Surgical 
Related
Environment
Immuno-
suppression
Concomitant 
Other 
Infections
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The incidence of IFIs is especially high in LTRs. IFIs are a direct consequence of 
immunosuppression after solid organ transplantation. An investigation showed that fungal 
infections occur in 15-35% of lung transplantations with a 60% overall mortality (11). 
1.3  CURRENT THERAPIES FOR INVASIVE FUNGAL INFECTIONS 
A few medications have been approved by the FDA for prophylaxis or treatment of lung 
infections, including echinocandins, amphotericin, flucytosine and azoles. Voriconazole and 
liposomal amphotericin B are recommended as the primary therapy for IFIs currently (12). These 
drugs have certain limitations as summarized in Table 1. For example, voriconazole is involved 
is metabolized by CYP2C19, CYP2C9 and CYP3A4 and involved in a number of drug 
interactions. Amphotericin B is well known for its severe and potentially lethal side effects and 
low response rate of 35%. Flucytosine has to be used with other antifungal agents due to 
preexisting or emerging resistance. Echinocandins are only available for intravenous 
administration (13). 
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Table 1. Disadvantages of current antifungal agents  
Agent Profiles 
Polyenes 
Amphotericin B  
    
Physiochemical: MW: 924, LogP: 0.8, pka1: 5.5 
Only available for intravenous administration.  
PK parameters: different formulations possess unique PK profiles.  
Well known for its severe nephrotoxicity and infusion related reactions.  
Pyrimidine analogues 
Flucytosine  
   
Physiochemical: MW: 129 , LogP: -1.1, pKa: 3.26 
Only available for oral formulation. 
PK parameters: half-life 2.4 to 4.8 hours, linear correlation between the elimination rate 
constant of flucytosine and creatinine clearance, widely distributes in body water (volumes of 
distribution from 0.6 to 0.9 L/kg 
Preexisting or emerging resistance is common, must be combined with another antifungal. 
Echinocandins 
Caspofungin  
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Physiochemical: MW: 1093, LogP: -4.82 
Only available for intravenous administration. 
PK parameters: half-life 9-11 hours, clearance: 12 mL/min, volume of distribution: 9.67L  
Significant acquisition costs. 
Azole 
Fluconazole  
 
Physiochemical: MW: 306, LogP: 0.4, pKa2: 1.76 
Available for intravenous and oral administration.  
PK parameters: half-life 30 hours, clearance: 15 mL/min, volume of distribution: 50 L  
Absence of activity against Aspergillus spp.; frequently reduced or absent activity against 
Candida glabrata; inherent resistance of Candida krusei. 
 
Itraconazole 
 
 
 
 
 
 
Physiochemical: MW: 706 , LogP: 5.66, pKa: 3.7 
  9 
Available for intravenous and oral administration.  
PK parameters: half-life 21hours, clearance: 381 mL/min, volume of distribution: 796 L 
FDA black box warning for heart failure; Capsule formulation highly variable; Acid-
dependant oral bioavailability leads to subtherapeutic; concentrations in critically ill patients 
with elevated gastric pH; solution improves bioavailability, but associated with 
gastrointestinal intolerance. 
Voriconazole  
 
Physiochemical: MW: 349 , LogP: 1, pKa: 2.27 
Available for intravenous and oral administration.  
PK parameters: half-life 21hours, clearance: 338 mL/min, volume of distribution: 4.6 L/kg 
Voriconazole is metabolized by CYP2C19, 2C9, 3A4). Highly variable pharmacokinetics  
Involved in a number of drug interactions. 
 
Note: information of the table is from package insert of individual drug and www.drugbank.ca, except other 
expcification. 
1https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Datasheet/6/a9528dat.pdf 
2 http://www.pfizer.ca/sites/g/files/g10017036/f/201410/DIFLUCAN%282%29.pdf 
  
  10 
1.4  POSACONAZOLE  
1.4.1 Posaconazole: a Promising First-line Prophylaxis and Treatment for Invasive 
Fungal Infections 
Posaconazole was initially approved by the FDA as a suspension in 2006 for prophylaxis of 
invasive Aspergillus and Candida infections in patients who are at high risk of developing these 
infections due to the immunocompromised status of the patients. Posaconazole is also a 
treatment for oropharyngeal candidiasis (OPC), including OPC refractory (rOPC) to itraconazole 
and/or fluconazole. Posaconazole is a potent and broad-spectrum triazole antifungal agent. It is 
effective against fungi that are refractory to other antifungal drugs. Posaconazole tablets and 
injection were approved in 2013 and 2014, respectively (Table 2). 
 
Table 2. FDA approved formulations of posaconazole 
Formulation Strength Approval date 
Suspension 40 mg/mL Sep. 2006 
Tablet, Delayed- release 100 mg Nov. 2013 
Injection 300mg per 16.7 mL Mar. 2014 
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1.4.2 Posaconazole Property and Mechanism of Its Antifungal Action 
 
Figure 3. Structure of posaconazole 
 
Posaconazole is a lipophilic drug with a logP of 5.4, pKa1 of 3.6 (piperazine) and pKa2 of 4.6 
(triazole) (14). It belongs to class II in the biopharmaceutical drug classification system, which 
means posaconazole has low solubility and high permeability. The molecular structure is shown 
in Figure 4. 
As with other triazole antifungal agents, posaconazole works by binding to the heme 
cofactor located on the active site of the cytochrome P450 (CYP)-dependent 14α-demethylase, 
an enzyme responsible for the conversion of lanosterol to 14α-dimethyl lanosterol in the 
ergosterol biosynthetic pathway (Fig. 5). Ergosterol is an essential component of the fungal cell 
membrane; therefore, inhibition of synthesis of ergosterol leads to disruption of the integrity and 
function of the fungal cell membrane, as well as inhibition of fungal growth (15). 
 
Figure 4. Mechanism of antifungal action of posaconazole 
Mechanism of Action 
 
   lanosterol 
14α-dimethyl  
lanosterol 
ergosterol 
14α- 
demethylase 
 
Ergosterol: an essential component of fungal cell 
membrane. 
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1.4.3 Pharmacokinetic Profiles of Posaconazole  
The pharmacokinetics properties of posaconazole are listed in Table 3. 
Table 3. Summary of posaconazole pharmacokinetic profiles 
Parameter Pharmacokinetic Profile 
Absorption The peak of plasma concentration was observed around 3-5 hours following 
administration of the oral suspension.  
Absorption is significantly improved when administered with food.  
Distribution Large apparent volume distribution (261 L). 
Posaconazole is highly protein bound (98.2%), mainly to albumin. 
Metabolism Primarily by glucuronidation; 
P-gp substrate.  
CYP3A4 inhibitor. 
Elimination In healthy volunteers, after intravenous injection, the clearance was 6.5 L/h with a 
half-life of 24 h. 
Mainly eliminated in feces with the parent drug as the major component. 
 
1.4.3.1 Absorption 
The peak of plasma concentration of posaconazole (Cmax) is normally observed around 3-5 hours 
following administration of an oral suspension. Both Cmax and area under curve (AUC) are 
significantly higher when posaconazole is administrated with food, therefore whenever possible, 
posacoazole suspension should be taken after a full meal (16). Because posaconazole AUC can 
be markedly improved by smaller multiple daily doses (17), two or three doses per day are 
recommended, although posaconazole has a long half-life. Besides food and dosing frequency, 
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posaconazole absorption can be affected by gastric pH. For example, proton pump inhibitors can 
decrease posaconazole absorption (18). Given that gastric acid suppression therapy is common 
among patients undergoing transplantation, we would anticipate poor absorption of posaconazole 
in this patient population.  
There is no data available regarding to the relative bioavailability of posaconazole 
suspension, however, we predict that posaconazole suspension has a low bioavailability due to 
its low solubility, being a substrate of P-gp efflux, and due to gut metabolism by UGT phase II 
enzymes.  
Recently a delayed-release tablet was developed with improved absorption and 
bioavailability of posaconazole. The pharmacokinetics of tablet has been evaluated in healthy 
volunteers. Under fasting condition, the AUC and Cmax for the tablet were slightly higher than the 
suspension. However, under fed condition, the AUC and Cmax for the tablet were 3 times higher 
than the suspension, and tablet showed less variability in exposure compared to the suspension 
(19). The absolute bioavailability of the delayed-release tablet is 54% under fasting conditions 
(16). 
1.4.3.2 Distribution 
Posaconazole has a large volume distribution and is also highly bound to albumin (20). The 
average volume distribution is 261 L, after intravenous administration. Posaconazole is 
distributed to pulmonary tissue and alveolar cells (21). 
1.4.3.3 Metabolism 
In healthy subjects, posaconazole has a mean half-life about 24 hours, but no half-life is reported 
in patients following intravenous injection. Posaconazole mainly circulates in the blood as the 
parent compound. Unlike other triazole antifungal agents, posaconazole is not metabolized by 
  14 
cytochrome P450 enzyme. Only about 17% of the administered posaconazole is metabolized by 
UDP-glucuronosyl transferase (UGT) 1A4 (22, 23), and its glucuronide metabolites have no 
antifungal activities (24). Compared with other triazole antifungal agents, posacoazole has fewer 
drug-drug interactions so its pharmacokinetic parameters are less influenced when co-
administrated with other drugs. However, posaconazole is a substrate of P-glycoprotein (P-gp) 
mediated efflux (16), and when P-gp function is altered by either endogenous or exogenous 
compounds, posaconazole pharmacokinetic parameters will be altered. In healthy volunteers, 
after a single intravenous injection of 200 mg, the total body clearance was 6.5 L/h (16). But 
clearance of posaconazole after intravenous injection has not been reported in patients. 
1.4.3.4 Excretion 
In one study, after administration of a radiolabeled suspension dosage form, 76.9% of 
administrated posaconazole was excreted in feces (66.3% was posaconazole). Meanwhile, the 
urinary excretion of posaconazole was negligible (24). 
1.4.4 Safety of posaconazole  
The most frequently observed adverse events in patients using posaconazole were diarrhea, 
hypokalemia, pyrexia and nausea in clinical trials. Mild to moderate elevations in alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) have also been reported in 
clinical trials. Therefore patient’s liver function should be assessed at the onset of posaconazole 
therapy and monitored during treatment (16). Like other azole antifungal agents, posaconazole 
can prolong QT interval and can lead to arrhythmias (16).  
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1.4.5 A Large Variation Is Observed in The Systemic Exposure of Posaconazole in LTRs 
Recent clinical studies have demonstrated an association between plasma concentrations of 
posaconazole and clinical response (25-27). According to the FDA pharmacological review, a 
steady state average concentration below 700 ng/mL is expected to result in breakthrough 
invasive fungal infections of more than 25% of patients. Our lab routinely measures 
posaconazole plasma concentrations in transplant patients as part of a therapeutic drug 
monitoring program. Over a period of ten months, we have observed posaconazole 
concentrations to be below 700 ng/mL in more than 60% of the patient samples (Fig. 6). Lung 
transplant patients have a high risk for invasive fungal infections with subtherapeutic 
posaconazole concentrations (28).  
                        
Figure 5. Distribution of posaconazole plasma trough concentrations measured at our lab 
 
The above distribution pattern of posaconazole concentrations was observed in 66 patient 
samples over a period of ten months. Posaconazole plasma trough concentrations were < 0.7 
μg/mL (The blue line, therapeutic threshold) in more than 60% of LTRs. The distribution 
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demonstrates posaconazole suspension didn’t produce sufficient plasma concentration, which 
puts patients at high risk for invasive fungal infection after transplantation. 
1.5 CYSTIC FIBROSIS 
Cystic fibrosis is an autosomal recessive genetic disorder that primarily affects the lungs and 
digestive system (Fig. 3). In patients with CF, a defective gene causes the body to produce 
unusually thick, sticky mucus that clogs the lungs and leads to life-threatening lung infections. 
Lung transplantation is a treatment for patients with advanced CF. Between 1995 and 2011, CF 
was the third most common reason for lung transplant, with an overall rate of 16.7% (6). 
 
 
Figure 6. Health problem of cystic fibrosis 
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Resource: http://en.wikipedia.org/wiki/Cystic_fibrosis 
1.5.1  Pharmacokinetic Studies in CF Patients 
Lower plasma concentrations of many drugs have been reported in patients with CF. The altered 
pharmacokinetics of drugs in CF patients are the results of multiple factors. It is well-known that 
CF patients are malnutrished due to malabsorption in the intestinal tract (29). The main cause of 
malabsorption is pancreatic insufficiency, so CF patients normally receive pancreatic enzyme 
supplement to facilitate absorption of nutrients (30). Decreased absorption of drugs in CF 
patients similar to malabsorption of nutrients has been speculated. In fact, there are many 
pathological changes in CF patients that can affect drug absorption, such as a more acidic 
circumstance in the duodenum, insufficient pancreatic enzymes secretion, altered bile acid 
turnover and a prolonged intestinal mobility (31). Therefore, drugs with different physiochemical 
property may demonstrate variable absorption in CF patients. 
Poor absorption, larger volume distribution and high total body clearance of certain drugs 
in patients with CF may explain the observed lower plasma concentrations of several drugs in 
patients with CF (32-34). However, the mechanism behind the altered pharmacokinetic profiles 
of many drugs in CF patients has not been completely evaluated. Many studies have investigated 
pharmacokinetics changes in CF patients, but the results are conflicting. 
Pharmacokinetics of oral ciprofloxacin has been studied in six CF patients and six 
healthy control subjects, closely matched with age, sex and weight. There was no statistical 
differences in dose normalized plasma area under curve (AUC), maximum plasma concentration 
(Cmax), half-life, total body clearance, renal clearance, and volume of distribution of 
ciprofloxacin between CF and the control group (35). 
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One study demonstrated a significantly lower serum concentration of cloxacillin in CF 
patients accompanied by dramatically increased total body clearance. However, no significant 
difference in the bioavailability of cloxacillin was observed in CF group compared with non-CF 
group after patients intravenous and oral administeration of cloxacillin (36). 
1.5.2 Pharmacokinetic Studies in LTRs With CF 
To date, limited information is available regarding the pharmacokinetics of drugs in LTRs with 
CF. Three pharmacokinetic studies have been conducted in this patient population but only one 
study compared the pharmacokinetics to a group of control subjects (37-39). That study was 
designed to assess the pharmacokinetics of tacrolimus in 22 LTRs (11 with CF and 11 without 
CF) (39). In the study, the CF group required a higher dose of tacrolimus to achieve similar drug 
exposure compared to non-CF group, and after dose normalization, AUC and Cmax were 
significantly lower in CF group compared to the non-CF group. Higher apparent total body 
clearance and larger apparent volume of distribution were reported in the CF group.   
1.5.3 Pharmacokinetics of Antifungal Agents in CF Patients 
Although there is a high incidence of IFIs in CF patients, there are very few studies that have 
investigated pharmacokinetic profiles of antifungal agents in this patient population. Only three 
studies have been performed, but none of them compared the pharmacokinetics of antifungal 
drugs in CF patients with a control group. 
The pharmacokinetics and safety of oral itraconazole was evaluated in 17 patients with 
CF. Despite receiving the recommended dosages of the oral solution, 11 of the patients did not 
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reach the target therapeutic threshold at steady state (40). The pharmacokinetics itraconazole 
after administration of capsule and oral solution were assessed in 30 CF patients. Although the 
patients received standard dosage of itraconazole, one half of the plasma samples had 
concentrations below the limit of detection (0.04 mg/L) (41). The recommended breakpoint of 
Ctrough for itraconazole is 0.5 mg/L (42). 
A retrospective study reported the plasma trough concentration of voriconazole in CF 
patients after lung transplantation. Following the standard dosing regimen (400 mg/day), in 30% 
of the 35 CF patients the plasma concentration was lower than 0.5 mg/L (therapeutic 
concentration is 1-2 mg/L). Even after increasing the dose (570 ± 160 mg/day), 40% of these 
patients did not reach target plasma concentrations 16 days later (38). 
No study has been performed to investigate the pharmacokinetic alterations of antifungal 
agents in LTRs with CF. Our goal is to compare the pharmacokinetics of posaconazole in LTRs 
with and without CF in order to improve treatment outcome with posaconazole. Because of the 
physiochemical property of posaconazole, a lipophilic drug with low solubility, we anticipated 
poor absorption of posaconazole in LTRs with CF, which exposes these patients to higher risk 
for IFIs.  
We hypothesize that LTRs with CF will have a significantly lower systemic exposure 
compared with LTRs without CF following oral administration of posaconazole suspension due 
to pathophysiological changes observed in CF. Our aims were as follows, 
Specific aim 1 was to develop and validate a simple and sensitive analytical method to quantify 
plasma concentrations of posaconazole in clinical samples. 
Specific aim 2 was to investigate the pharmacokinetic difference in LTRs with and without CF. 
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2.0  MATERIALS AND METHODS 
2.1 CHEMICALS 
Posaconazole was a gift from the Schering-Plough (Wicklow, Ireland). The itraconazole that was 
used as an internal standard (IS) was a gift from Janssen-Cilag (Beerse, Belgium). Acetonitrile, 
methanol, and water, all HPLC Grade, were purchased from Sigma-Aldrich. Formic acid, 
reagent grade, was also purchased from Sigma-Aldrich. Pooled human plasma was obtained 
from the central lab at the University of Pittsburgh Medical Center (Pennsylvania, USA). 
Ultrapure water was obtained from Milli-Q water purification system. 
A Symmetry C18 column (4.6×250 mm) was purchased from Waters; solid phase 
extraction (SPE) cartridges (Oasis, Hydrophilic-Lipophilic-Balanced, reverse-phase sorbent, 1cc/ 
30 mg) were also purchased from Waters. 
2.2 METHOD FOR POSACONAZOLE ASSAY 
2.2.1 Sample Preparation 
Posaconazole stock solution with a concentration of 10 mg/mL was prepared in methanol and 
was diluted with methanol to obtain 0.02, 0.05, 0.1, 0.2, 0.5, 1.0, and 3.0 mg/mL as working 
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solutions. Posaconazole working solutions were spiked into pooled human plasma to obtain 
samples at concentrations of 0.02, 0.05, 0.1, 0.2, 0.5, 1.0, and 3.0 μg/mL as calibration standards. 
Stock solution for quality controls (QCs) with a concentration of 4.9 mg/mL was prepared in 
methanol and was diluted with methanol afterwards to obtain 0.049, 0.49, and 2.94 mg/mL as 
working solutions. These working solutions were spiked into pooled human plasma to obtain 
samples with the concentrations of 0.049, 0.49, and 2.94 μg/mL as QCs. IS stock solution 400 
μg/mL in methanol was diluted to 8 μg/mL with 50% methanol. In safe-lock tubes, these stock 
solutions, working solutions, calibration standards, and QCs were frozen at –20°C.  
Plasma posaconazole concentrations were determined by a reverse-phase HPLC with a 
fluorescence detector. Standard curves were prepared by spiking blank human plasma with 
posaconazole working solutions. Internal standard 25μL was added to each sample. Solid phase 
extraction cartridges loaded with 200μL plasma samples, were washed independently with 50% 
methanol and then the posaconazole and IS were eluted with 100% methanol. The eluent was 
dried under a stream of air. The dried residues were reconstituted into 100 μL with acetonitrile 
and water (60:40, v: v). 
2.2.2 HPLC Analysis Conditions 
The system consisted of Waters 2695 HPLC separation module and Waster 2475 fluorescence 
detector. Excitation and emission wavelengths were set as 258 and 350 nm, respectively. A 
Symmetry C18 column was used together with a 0.5-mm precolumn filter. The column oven was 
set to 40°C, the injection volume was 20 μL, and the autosampler tray was set to 10°C. The 
compounds were separated with 25% of A consisting of water: acetonitrile (95:5, v:v) with 
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formic acid at a pH of 2, and 75% of B consisting acetonitrile: formic acid (100: 0.1, v: v), as 
mobile phase. The mobile phase flow rate was 1.2 mL/min. 
2.2.3 Validation Procedures 
The HPLC-fluorescence method was optimized for emission and excitation wavelengths, and 
pH, and validated by selectivity, linearity, precision, accuracy, recovery, and stability. 
Emission, excitation wavelengths, and pH optimization were performed by comparing the 
signal intensity of posaconazole and IS by changing different combinations of emission, 
excitation wavelengths, and pH. Samples for study of emission, excitation wavelengths, and pH 
optimization were prepared by spiking posaconazole and IS working solutions into reconstitution 
medium. Selectivity was performed by analyzing pooled human blank plasma from six 
individuals in order to exclude potential interference from any endogenous substances in the 
assay. (What about other drug interference?) 
Linearity was studied by assessing linear regression of HPLC response and posaconazole 
concentration in a range of 0.02-3.0 μg/mL. Samples for linearity study were prepared by spiking 
IS into calibration standards at series of concentrations (0.02, 0.05, 0.1, 0.2, 0.5, 1, and 3 μg/mL) 
and samples were processed as described in the sample preparation section. The peak area ratios 
of the posaconazole against the IS were plotted against posaconazole concentration. Weighting 
of 1/response was applied during the regression analysis. 
The lowest limit of quantification (LLOQ) was evaluated by using five samples from the 
calibration standards at 0.02 μg/mL to analyze if the back-calculated concentrations have the 
precision that are within 20% of CV and have the accuracy within 20% of 0.02 μg/mL. 
Precision included intra- and inter-day reproducibility. QCs of three different 
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concentrations (0.049, 0.49, and 2.94 μg/mL) were tested. For intra-day precision, three samples 
of each concentration were assayed on a single day; for inter-day precisions, six samples of each 
concentration were measured on three consecutive days. The intra-day and inter-day coefficient 
of variations were within 15%. 
Accuracy included intra- and inter-day accuracy. QCs of three different concentrations 
(0.049, 0.49, and 2.94 μg/mL) were tested. For intra-day accuracy, three samples of each 
concentration were assayed on a single day; for inter-day accuracy, six samples of each 
concentration were measured on three consecutive days. The intra-day and inter-day accuracy 
were within 85% to 115% of the nominal values.  
Recovery experiments (extraction efficiency) were performed by comparing the 
responses of extracted QC samples (0.049, 0.49, and 2.94 μg/mL) with the response of 
corresponding concentrations of posaconazole in eluent obtained from extracted blank human 
plasma that represents 100% recovery. 
The stability of posaconazole QCs at low and high concentrations were assessed under 
three freeze-thaw cycles, placing samples on room temperature for 24 hours and remaining 
processed samples in the autosampler for 16 hours. 
2.3 SYNOPSIS OF CLINICAL PROTOCOL  
Title of Study Pharmacokinetic Analysis of Posaconazole in LTRs  
Number of Planned 
Subjects 
A total enrollment of 20 patients 
10 patients in each of the following groups will be enrolled:  
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1) LTRs with CF 
2) LTRs without CF as controls 
Study Model A single-center, two-cohort, prospective and observational study. 
Primary Objectives To characterize the PK of posaconazole in LTRs on a fixed-dose 
regimen in order to determine the extent of interpatient variability 
and factors that lead to interpatient variability in plasma levels. 
Subject Selection 
Criteria 
Primary Inclusion criteria: 
 Inform consented; 
 ≥18 years old; 
 Initiation of posaconazole prophylaxis following lung 
transplantation. 
Primary Exclusion criteria: 
 Received posaconazole within the previous 30 days. 
Study Therapies Posaconazole suspension ( NOXAFIL® ) 400 mg b.i.d. 
Blood sampling  Serial blood samples (3 mL) will be collected in heparinized tubes 
from each patient just prior to (0 h) and at 2, 4, 6, 8, and 12 h 
following administration of a minimum of five days of treatment.  
Blood Samples 
Processing 
The exact time of the blood draw will be recorded, and blood 
samples will be placed in ice and subsequently centrifuged at 
1,000g for 10 min, and the plasma stored at − 80°C until they are 
assayed.  
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2.4 POSACONAZOLE PHARMACOKINETIC AND STATISTICAL ANALYSES 
Posaconazole pharmacokinetic analyses Pharmacokinetic analyses were performed using 
Phoenix WinNonlin® 6.4. Maximum plasma concentration at steady state (Css, max), time to Css, 
max (Tmax), minimum plasma concentration at steady state (Css, min), and elimination rate constant 
k were obtained from Phoenix WinNonlin®. Posaconazole plasma concentrations were used to 
determine the pharmacokinetic parameters using a non-compartment model. Maximum plasma 
concentration at steady state (Css, max), time to Css, max (Tmax), minimum plasma concentration at 
steady state (Css, min) after five doses were obtained from each patient’s plasma concentration-
time profile. Ctrough was defined as concentration at time zero. Area under plasma concentration 
versus time curve (AUC) was determined from time zero (0 h) to 12 h or to 8 h using the 
trapezoidal method. Average concentration at steady state (Css, av) was calculated by AUC0-24/24. 
There was some deviation from the protocol regarding dosing and blood sampling time, 
therefore, sometimes plasma concentrations at 12 h or 8 h were extrapolated using the 
elimination rate constant k; plasma concentrations at 0 h were assumed to be identical to the 
concentrations at 12 h or 8 h at steady state whenever necessary. Oral clearance (CL/F) was 
calculated according to the equation CL/F = Daily Dose/AUC0-24. 
Statistic analyses Statistic analyses were conducted using GraphPad Prism 6.0. Mann-Whitney 
non-parametric test was applied to compare the difference in pharmacokinetic parameters 
between LTRs with or without CF. A P value of < 0.05 was considered statistically significant.  
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3.0  RESULTS 
3.1 DETERMINATION OF EMISSION, EXCITATION AND OPTIMAL PH 
Optimal emission, excitation and pH were evaluated by spiking posaconazole and IS working 
solutions into reconstitution solution to obtain posaconazole at 6 μg/mL and IS at 4μg/mL. 
Injection volume was 10 μL. 
We observed excitation and emission peaks at 258 nm and 321 nm, respectively, after 
wavelength scans for excitation and emission (Fig. 7). To the best of our knowledge, there are 
two publications using HPLC with fluorescence detection for posaconazole quantification. They 
reported using excitation 260 nm, emission 350 nm, and excitation wavelength 240 nm, emission 
wavelength 385 nm, respectively (43, 44). We optimized the emission wavelength and pH to get 
a good response from both posaconazole and IS from a fluorescence detector.  
When pH of the mobile phase was greater than 3.5, it was difficult to detect the peaks of 
posaconazole and IS. In this experiment, we fixed the excitation wavelength at 258 nm to 
optimize emission wavelength and pH. The results showed when excitation was fixed at 258nm, 
the response of posaconazole and IS were at the maximum with an emission wavelength of 350 
nm and a pH of 2 (Table 4).  
 
 
  27 
 
Figure 7. Excitation and emission wavelength scan 
 
  
Excitation Wavelength Scan 
 
Emission Wavelength Scan
 
258.5
317.0
323.5
E
U
0.00
20.00
40.00
60.00
80.00
nm
200.00 220.00 240.00 260.00 280.00 300.00 320.00
321.2
667.0
E
U
-20.00
0.00
20.00
40.00
60.00
80.00
100.00
nm
300.00 400.00 500.00 600.00 700.00 800.00
28 
 
Table 4. PH and emission optimization 
 
 
 
 
 
 
 
 
 
 
 
3.2       METHOD VALIDATION 
3.2.1 Selectivity 
Posaconazole and IS were eluted at 2.3 min and 3.3 min, respectively with sharp and symmetric 
peaks using the HPLC method described above. No interference peaks were found at the retention 
time of posaconazole and IS in pooled blank human plasma (Fig. 8).  
 
PH Wavelength (nm) Posaconazole Area IS Area 
PH=3.5 Ex258/Em321 76611 Hard to detect peak 
Ex258/Em385 3174348 5372943 
Ex258/Em350 3568617 4406309 
PH=3 Ex258/Em321 334689 Hard to detect peak 
Ex258/Em385 5301558 5528465 
Ex258/Em350 8929110 9580873 
PH=2.5 Ex258/Em321 Hard to detect peak Hard to detect peak 
Ex258/Em385 4923988 5068319 
Ex258/Em350 8685634 9731927 
PH=2 Ex258/Em321 9825702 138057161 
Ex258/Em385 108036 Hard to detect peak 
Ex258/Em350 11299093 10237234 
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Figure 8. Representative chromatogram (A) Pooled blank human plasma; (B) Standard calibration 
sample (3.0 μg/mL of posaconazole); (C) One patient sample 
 
 
A 
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3.2.2 Linearity 
Linearity was tested by spiking IS into calibration standards at series of concentrations (0.02, 
0.05, 0.1, 0.2, 0.5, 1, 3 μg/mL) and samples were processed as described in method section. The 
peak area ratios of the posaconazole to the IS were plotted against analyte concentration (least 
squares linear regression). A weighting factor of 1/response was applied. A linear response was 
observed over the calibration range (r2 > 0.99) (Table 5). 
Table 5. Linearity data of posaconazole in pooled human plasma 
Nominal Conc. 
(μg/mL) POSA/IS  POSA/ IS  POSA/ IS  POSA/IS  POSA/IS  
0.02 0.028 0.024 0.027 0.025 0.030 
0.05 0.066 0.066 0.068 0.052 0.059 
0.1 0.113 0.104 0.110 0.109 0.114 
0.2 0.192 0.188 0.179 0.194 0.204 
0.5 0.519 0.511 0.465 0.493 0.502 
1 1.092 1.073 1.162 1.090 1.109 
3 2.938 2.841 3.034 2.993 3.101 
Weighting: 1/y 
Equation 
Y=1.001X+ 
0.01039 
Y=0.9745+ 
0.008597 
Y=1.026X+ 
0.00703 
Y=1.012X+ 
0.003738 
Y=1.040X+ 
0.007888 
r2 0.9974 0.9965 0.9932 0.9982 0.9987 
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3.2.3 Precision 
The intra-day and inter-day precisions were within 15% of the coefficient of variation (CV) 
(Table 6, 7).  
Table 6. Intra-day precision of posaconazole in pooled human plasma (expressed as CV%, n=3) 
Nominal Conc. 
(μg/mL) 
Calculated Conc. 
(μg/mL) Mean (μg/mL) SD (μg/mL) CV (%) 
0.049 
 
0.054 0.054 0.001 2.0 
0.054       
0.052       
0.49 
 
0.550 0.521 0.028 5.3 
0.517       
0.496       
2.94 
 
3.003 2.859 0.126 4.4 
2.806       
2.768       
CV%=standard deviation/mean×100%; 
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Table 7. Inter-day precision of posaconazole in pooled human plasma (expressed as CV%, n = 6) 
Nominal Conc. 
(μg/mL) 
Calculated 
Conc. (μg/mL) 
Mean (μg/mL) SD (μg/mL) CV (%) 
0.049 
 
0.054 0.052 0.006 10.8 
0.054 
   
0.052 
   
0.045 
   
0.060 
   
0.045 
   
0.49 
 
0.550 0.498 0.031 6.3 
0.517 
   
0.496 
   
0.472 
   
0.478 
   
0.472 
   
2.94 
 
3.003 2.778 0.144 5.2 
2.806 
   
2.768 
   
2.749 
   
2.551 
   
2.791 
   
CV%=standard deviation/mean×100%; 
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3.2.4 Accuracy 
The intra-day and inter-day accuracy were within 85% to 115% of the nominal values of QC 
samples (Table 8, 9).  
Table 8. Intra-day accuracy of posaconazole in pooled human plasma (expressed as percent of 
nominal concentration, n = 3) 
Nominal Conc. 
(μg/mL) 
Calculated Conc. 
(μg/mL) % of Nominal Conc. 
Mean of % of 
Nominal 
Conc. SD (%) 
0.049 
 
0.054 111.0 109.2 2.2 
0.054 109.8     
0.052 106.8     
0.49 
 
0.550 112.3 106.4 5.6 
0.517 105.6     
0.496 101.2     
2.94 
 
3.003 102.1 97.2 4.3 
2.806 95.5     
2.768 94.2     
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Table 9. Inter-day accuracy of posaconazole in pooled human plasma (expressed as percent of nominal 
concentration, n = 6) 
 
 
 
Nominal 
Conc. (μg/mL) 
Calculated Conc. 
(μg/mL) 
% of Nominal 
Conc. 
Mean of % of 
Nominal Conc. 
SD (%) 
0.049 
 
0.054 111.0 105.6 11.4 
0.054 109.8   
0.052 106.8   
0.045 92.1   
0.060 121.4   
0.045 92.6   
0.49 
 
0.550 112.3 101.6 6.4 
0.517 105.6   
0.496 101.2   
0.472 96.2   
0.478 97.6   
0.472 96.4   
2.94 
 
3.003 102.1 94.5 4.9 
2.806 95.5   
2.768 94.1   
2.749 93.5   
2.551 86.8   
2.791 95.0   
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3.2.5  Recovery 
The mean recovery of posaconazole in three QC concentrations were in the range 86.21–105.96% 
(Table 10). 
Table 10. Recovery data of posaconazole 
 
  
Conc. 
(μg/mL) 
POSA 
AREA IS AREA RATIO 
Mean 
RATIO 
Recovery  
(%) 
After extraction of QC 
samples, spike IS into 
eluent, evaporate and 
reconstitute as 
described in method 
section.  
0.049 
 
455657 10480984 0.0435 0.043 106 
396451 10433095 0.0380     
494735 10390469 0.0476     
0.49 
 
4642214 10823417 0.4289 0.421 86 
4595010 10964174 0.4191     
4583174 11087297 0.4134     
2.94 
 
25888591 10699642 2.4196 2.379 89 
26004189 10888182 2.3883     
24258448 10412266 2.3298     
Spike posaconazole 
and IS into extracted 
blank plasma, 
evaporate and 
reconstitute as 
described in method 
section 
0.049 
 
404749 10546872 0.0384 0.041   
470954 10830538 0.0435     
432906 10830538 0.0400     
0.49 
 
5213640 10438718 0.4995 0.488   
5171392 10777765 0.4798     
5270551 10893464 0.4838     
2.94 
 
29682732 11132868 2.6662 2.675   
29791933 10838863 2.7486     
29872087 11448286 2.6093     
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3.2.6 Lower Limit of Quantification (LLOQ) 
The LLOQ was measured using five samples. The back-calculated concentrations have precision 
and accuracy within 20% of the nominal concentration (Table 11). 
Table 11. Accuracy and precision of LLOQ (n=5) 
Nominal 
Conc. 
(μg/mL) 
Calculated 
Conc. (μg/mL) 
% of Nominal Conc. 
±SD CV (%) 
0.02 0.021 109.4±2.3 2.1 
0.02 0.022 
 
 0.02 0.022 
 0.02 0.022 
 0.02 0.022 
 CV%=standard deviation/mean×100%;  
 
3.2.7 Stability 
Stability was assessed through three cycles of freeze and thaw stability test, as well as a bench-
top stability test, and a processed sample stability test. The changes in the QC samples of 
posaconazole concentrations were within 15% of nominal concentrations (Table 12). 
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Table 12. Stability of posaconazole QC samples 
  
Nominal Conc. 
(μg/mL) 
Calculated Conc.  
(μg/mL) RE (%) 
3 cycles of 
Freeze/ thaw 
0.049 
 
0.046 -6.1 
0.048 -1.5 
0.045 -7.7 
2.94 
 
2.753 -6.4 
2.872 -2.3 
2.971 1.0 
24 hours room 
temperature 
0.049 
 
0.044 -10.6 
0.044 -10.6 
0.048 -2.4 
2.94 
 
2.857 -2.8 
2.871 -2.4 
2.875 -2.2 
Re-injection 
after 16 hours 
0.049 
 
0.054 10.9 
0.053 8.7 
0.053 7.3 
2.94 
 
2.942 0.1 
2.936 -0.2 
2.965 0.9 
RE%= ((calculated concentration−nominal concentration)/(nominal concentration))×100% 
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3.2.8 Quality Controls 
The samples below were applied as quality controls when measuring patient samples (Table 13). 
 
Table 13. Accuracy of QCs 
Nominal Conc. (μg/mL) Calculated Conc. (μg/mL) RE(%) 
Day 1 
0.049 0.063 28.1 
0.49 0.564 15.1 
2.94 2.703 -8.1 
Day 2 
0.049 0.0575 17.3 
0.49 0.5163 5.4 
2.94 2.7063 -8.0 
Day 3 
0.049 0.0517 5.6 
0.049 0.0518 5.7 
0.49 0.5401 10.2 
0.49 0.5118 4.5 
2.94 2.8920 -1.6 
2.94 2.7761 -5.6 
Day 4 
0.049 0.053 8.2 
0.049 0.052 6.4 
0.49 0.538 9.7 
0.49 0.540 10.2 
2.94 2.88 -2.0 
2.94 2.92 -0.6 
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3.3 POSACONAZOLE PLASMA CONCENTRATIONS IN PATIENT SAMPLES 
3.3.1 Patient Demographic Data 
A total of 20 patients, including 7 LTRs with CF disease and 13 LTRs without CF disease were 
enrolled into the study. The summarized patient demographic data lists in Table 14. The mean 
age and weight of CF group are smaller than non CF group because patients with CF are under 
malnourished (45). 
Table 14. Patients demographic data 
Characteristic 
Value 
CF Group 
(n=7) 
Non-CF Group 
(n=13) 
Total 
(n=20) 
 
P value 
Mean Age [yr (range)] 36.1 (25-51) 60.7 (28-77) 52.1 (25-77) 0.0006 
Age Range 0.04 
      ≥ 18 to < 65 [n (%)] 7 (100%) 7 (54%) 14 (70%) 
      ≥ 65 [n (%)] 0 6 (46%) 6 (30%) 
Sex [n (%)] 0.07 
      Female 5 (71%) 3 (23%) 8 (40%) 
      Male 2 (29%) 10 (76%) 12 (60%) 
Race [n (%)] 0.25 
      Caucasian 7 (100%) 10 (76%) 7 (85%) 
      Others 0 3 (23%) 3 (15%) 
Mean Weight [kg(range)] 56.66 (41.6-68) 78.15 (48.3-110) 70.63 (41.6-110) 0.01 
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3.3.2 Posaconaozle Plasma Concentrations in Lung Transplant Patients 
Posaconazole plasma concentrations-time profiles for 20 enrolled patients are listed in Figure 9. 
 
 
Figure 9. Posaconazole concentration - time profiles in 20 patients 
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3.4 PHARMACOKINETIC PARAMETERS OF POSACONAZOLE  
One patient from the non-CF cohort was excluded from the pharmacokinetic analysis due to 
administration of a second dose within 6 hours after the first dose. The typical dosing frequency 
of posaconazole suspension is twice daily, but 4 patients in CF group and 4 patients in non-CF 
group received a second dose of posaconazole around 8 hours after the first dose. To measure the 
area under the posaconazole plasma concentration-time curve from 0 to 12 hours or 0 to 8 hours 
at steady state, plasma concentrations at 12 hours (5 patients), and plasma concentrations at 8 
hours (5 patients) were extrapolated from last observed data and the elimination rate constant k. 
Plasma concentrations at 0 hour were assumed to be the same as the concentrations at 12 hours 
or 8 hours at steady state in 6 patients. After a minimum of five days treatment of posaconazole 
maximum plasma concentration Css, max (0.311 μg/mL) in CF patients was 56% lower compared 
to Css, max (0.699 μg/mL) in non-CF patients; the minimum plasma concentration Css, min 
(0.189·μg/mL) in CF patients was 60% lower compared to Css, min (0.474 μg/mL) in non-CF 
patients; the average plasma concentration Css, av (0.233 μg/mL) in CF patients was 61% lower 
compared to Css, av (0.594 μg/mL) in non-CF patients, the dose normalized plasma area under 
curve AUC0-24 (0.007 h*μg/mL) in CF patients was 65% lower compared to dose normalized 
AUC0-24 (0.02 h*μg/mL) in non-CF patient, and the apparent oral clearance of 2.51 L/h/kg in CF 
patients was 3.4 times higher compared to 0.74 L/h/kg in non-CF patients. We observed no 
significant difference of Tmax and apparent oral clearance (Table 15). Weight normalized 
apparent clearance however was significantly higher in CF patients. 
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Table 15. Pharmacokinetic parameters of posaconazole in CF and non-CF group (expressed as 
median (range)) 
Parameter CF cohort 
 N= 7 
Non-CF cohort 
N= 12 
P value 
Tmax (h) 4.4 (0-7.8) 4 (0-11.8) 0.4 
Css, max (μg/mL) 0.311 (0.021-0.968) 0.699 (0.227-2.983) NA* 
Css, min (μg/mL) 0.189 (0-0.619) 0.474 (0.115-2.094) NA* 
Css, av (μg/mL) 0.233 (0.01-0.772) 0.594 (0.154-2.455) 0.03 
AUC0-24 / Daily dose (h*μg/mL) 0.007 (0.0003-0.019) 0.02 (0.005-0.074) 0.02 
Oral clearance (L/h) 143.16 (32.26-3278.69) 51.83 (13.58-216.33) > 0.05 
Weight normalized oral clearance (L/h/kg) 2.51 (0.76-48.22) 0.74 (0.25-2.66) 0.005 
*NA: Not Applicable. Statistic analyses are not applicable to Css, max, and Css, min, because the enrolled patients didn’t 
follow same dose interval. 
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3.5 A GOOD CORRELATION BETWEEN CTROUGH AND AUC0-Τ 
Ctrough and AUC0-τ were well correlated (r
2 = 0.91, P < 0.0001) (Fig. 10).  
 
 
Figure 10. Correlation between Ctrough and AUC0-τ 
 
A good correlation between Ctrough and AUC0-τ demonstrates that measurement of 
posaconazole plasma concentration at trough when reaching steady state can predict 
posaconazole systemic exposure. It documents that Ctrough can be used as surrogate for 
therapeutic monitoring of posaconazole. 
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4.0  DISCUSSION 
Lung transplant recipients have a high risk for invasive fungal infections. At the University of 
Pittsburgh Medical Center, all LTRs receive routine antifungal prophylaxis with a triazole agent 
(voriconazole or posaconazole) for at least four to six months after transplantation. Posaconazole 
is an important antifungal agent for prophylaxis and treatment of invasive fungal infections. On 
one hand, posaconazole has potent and broad-spectrum activity against yeast and molds; on the 
other hand, posaconazole has fewer drug-drug interactions because it is not metabolized by 
cytochrome P450 enzymes. Now posaconazole is extensively used after transplantation for 
prophylaxis of invasive fungal infections and it is promising to become the first-line of therapy.  
According to pharmacology review of two phase 3 clinical trials by the FDA, the plasma 
exposure of posaconazole is associated with clinical response. A steady-state Cav of below 700 
ng/mL is expected to result in a 25% invasive fungal infection breakthrough rate (28). 
Posaconazole plasma exposure was proportionally increased when healthy volunteers were given 
50 mg to 400 mg b.i.d. in a multiple-dose study. But plasma exposure of posaconazole was not 
further increased following multiple doses from 400 mg to 600 mg b.i.d. in patients (16). The 
absorption limitation of posaconazole suspension is probably due to its poor solubility. The FDA 
suggests that if plasma concentration of posaconazole is below 0.7 μg /mL after patients receive 
a posaconazole suspension of 400 mg t.i.d. for 7 days, the regimen should be switched to other 
antifungal agents. 
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Besides posaconazole’s poor solubility, the absorption from a suspension can be affected 
by a number of variables. Firstly, high-fat meals and non-fat meals significantly increase plasma 
exposure of posaconazole. When patients are not allowed or not able to have a full meal while on 
posaconazole, they are at high risk for invasive fungal infection breakthrough due to low drug 
exposure. Secondly, drug-drug interactions can lead to low plasma exposure of posaconazole. 
Posaconazole is a substrate of P-gp efflux and is metabolized by UGT 1A4. Drugs that induce 
either UGT enzyme or P-gp efflux can decrease plasma exposure of posaconazole. The third 
factor is the pH of gastrointestinal tract in patients. When patients undergo acid-suppressive 
therapy, their plasma exposure of posaconazole is decreased. Given the unpredictable plasma 
exposure of posaconazole, therapeutic drug monitoring should be applied to posaconazole to 
individualize its dosing regimen (46-48). 
Patients with CF have increased invasive fungal infections after lung transplantation, but 
they are suspected to experience poor absorption of posaconazole. Most patients with CF have 
exocrine pancreatic insufficiency and altered bile acid turnover, which may affect the absorption 
of lipophilic drugs such as posaconazole (31). Due to the reasons above, it is imperative to 
understand pharmacokinetic profiles of posaconazole in lung transplant recipients with CF. This 
study is the first one to investigate pharmacokinetics of posaconazole suspension in lung 
transplant recipients with CF. 
In this study, we established a HPLC-fluorescence method to analyze plasma 
concentrations of posaconazole. The method is very sensitive. HPLC–ultraviolet (UV) and 
HPLC tandem mass spectrometer (MS) have been used to analyzed posaconazole (49-51). The 
HPLC–UV was not sensitive to measure posaconazole in patient samples. One study reported 
using HPLC-fluorescence to analyze posaconazole and itraconazole following liquid-liquid 
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extraction of its plasma samples (43). But an analytical interference was observed with this 
method for posaconazole in pooled human blank plasma. We evaluated different extraction 
reagents such as terbutylmethylether, hexane-dichloromethane and ethyl ether, but none of them 
solved the analytical problem. Finally, we developed solid phase extraction for sample 
extraction, and no interfering peaks appeared with the same retention time of posaconazole. In 
this method, out of 100 μL of reconstitution volume, the injection volume used is only 20 μL. 
This makes it possible to re-inject sample, if necessary. Since this assay requires only a small 
volume of plasma, it is favorable to both pharmacokinetic studies and therapeutic drug 
monitoring of posaconazole. There was no interfering endogenous materials in human plasma.. 
The probability for other drugs used with posaconazole to elute at same retention time and to 
interfere with posaconazole and itraconazole at the specific excitation and emission wavelengths 
and pH 2 used is rare. We tested chromatographic peaks of ketoconazole, fluconazole and 
voriconazole at the described chromatographic method, and these three drugs didn’t show any 
interfering peaks. 
In the label of posaconazole, it is recommended to avoid concomitant use of cimetidine 
(an H2-receptor antagonist) and esomeprazole (a proton pump inhibitor) with posaconazole oral 
suspension, because lower plasma concentrations have been observed when patients 
concomitantly used the two drugs with posaconazole suspension. In this study, none of the 
twenty patients were taking either of the two drugs during the pharmacokinetic study. 
In the study, we observed large variation in posaconazole pharmacokinetic parameters 
and lower Css, max, Css, min, Css, av, and dose normalized AUC0-24 in CF group. Among the CF 
patients, one patient did not receive any oral feeding, two patients were receiving tube feeding 
and the other four patients were normally feed during the pharmacokinetic study. In the non-CF 
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group, among 13 patients, 2 patients were tube fed and the other patients were normally feed. We 
observed a lower plasma concentration of posaconazole in the most of these patients not 
receiving normal feeding, but lower plasma concentration of posaconazole was also observed in 
patients with normal feeding. Because of the small sample size of patients, we can’t find 
association between feeding and plasma concentration of posaconazole.  
There was no statistic difference of total apparent oral clearance between the CF and non-
CF group, but we found significantly higher weight normalized total apparent oral clearance in 
the CF patients. Currently, there is no published literature reporting association between weight 
and total body clearance of posaconazole. Considering posaconazole is a highly lipophilic drug, 
a patient with greater weight may have a larger volume distribution. From this study, we believe 
weight may be a potential viability that could affect the total body exposure of posaconazole. But 
additional studies need to be performed to understand the impact of weight of the patient on the 
total body clearance of posaconazole.  
Several factors could result in a lower systemic exposure of posaconazole in patients with 
CF including absorption, glucuronidation, and reabsorption. Posaconazole is a lipophilic drug 
and the decreased pancreatic enzyme secretion and altered bile acid turnover in CF can lead to 
reduced absorption of posaconazole (24). Secondly, an enhanced activity of UGT1A4 in patients 
with CF may be one of the reasons behind a lower plasma concentration of posaconazole. Some 
studies reported the hepatic glucuronosyltransferase activity was increased in CF disease (52, 
53), but more data are needed to prove the observation and no study specifically assessed the 
alteration of UGT1A4 in CF. If UGT1A4 exhibits enhanced activity in CF, more posaconazole 
would be metabolized into its inactive glucuronide conjugates, leading to decreased plasma 
concentration of posaconazole. There are multiple factors that could affect posaconazole 
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reabsorption in CF patients. For example, a decreased activity of multidrug resistant protein 2, a 
major transporter responsible for the biliary excretion of glucuronides, could decrease the 
secretion of glucuronide conjugates from bile to intestine. Considering the altered microflora in 
the intestine, patient with CF may have a lower glucuronidase activity in the gut to convert 
posaconazole glucuronide to posaconazole for reabsorption. The alteration of glucuronidation, 
and reabsorption can be confirmed by quantifying glucuronide conjugates of posaconazole in 
plasma, but standard posaconazole glucouronide is not commercially available, currently. 
 Out of 20 patients, a steady state average concentration of 0.7 μg/mL was achieved only 
in one CF patient and three non-CF patients. The findings supports therapeutic drug monitoring 
of posaconazole is very important to LTRs, especially in LTRs with CF. Moreover, a good 
correlation between Ctrough and AUC0-τ demonstrated that Ctrough is a good surrogate marker to 
monitor systemic exposure of posaconazole. 
In conclusion, therapeutic drug monitoring of posaconazole should be applied to LTRs. If 
increasing the dosage of posaconazole suspension doesn’t help patients achieve desired target 
therapeutic level in patients, using a posaconazole tablet or switching to other antifungal agents 
should be considered. 
There are some limitations to this clinical study. First, for pharmacokinetic study, the 
time period of blood sampling should be 3 to 5 terminal elimination half-lives following the last 
dose. The half-life of posaconazole is 24 hours, so ideally blood samples should be collected at 
least 72 hours after the final dose. In this study, blood samples were only collected for 8 to 12 
hours after a dose. This is the reason that we observed flat time-concentration profiles, because 
concentration time profiles for posaconazole didn’t reach true terminal phase. This limitation 
was due to clinical practice of administrating of drug b.i.d or t.i.d. Second, the clearance assessed 
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from suspension is oral clearance, not true systemic clearance. Based on the oral clearance we 
could not conclude that CF patients have higher total body clearance for posaconazole or poor 
oral absorption. Now, posaoncaozle injection has been approved by the FDA. In the future, we 
could use the intravenous formulation to investigate true total body clearance of posaconazole in 
CF patients. Furthermore, if we had measured the glucuronide metabolite of posaconazole and 
analyzed the ratio of systemic exposure of metabolite against the parent drug, we would be able 
to understand if there are changes to posaconazole metabolism in LTRs with CF. Alterations to 
metabolic pathway could be one possible cause of low systemic exposure of posaconazole in 
LTRs with CF. 
In the past two decades, pulmonary drug delivery has been become a popular route 
because 70-140 m2 of lung surface could be an ideal drug absorption site in addition to small 
intestinal tract (54). From this study, we observed a low systemic exposure in LTRs. In the 
future, we could develop inhaled posaconazole to improve prophylaxis of IFIs in LTRs because 
localized posaconazole delivery by inhalation would increase intrapulmonary concentration of 
posaconazole and bypass gastrointestinal absorption. Due to bypassing gastrointestinal 
absorption, inhaled posaconazole will result in high drug concentration in the respiratory tract 
with low systemic exposure, which will enable posaconazole to have better therapeutic effect 
with fewer side effects. Moreover, an inhaled formulation would have fewer drug-drug 
interactions that are very common observed with triazole antifungal drugs due to their 
metabolism by cytochrome P450 enzyme. 
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